echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Novavax's COVID-19 vaccine is "very effective" against UK variants

    Novavax's COVID-19 vaccine is "very effective" against UK variants

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Novavax announced in its UK- based Phase III trial that its COVID-19 vaccine NVX-CoV2373 is 96.


    COVID-19

    This study recruited more than 15,000 18-84-year-old subjects, of which 27% were older than 65 years old.


    In addition to the final efficacy analysis of the original COVID-19 strain, Novavax also found that NVX-CoV2373 is 86.


    Stanley Erck, President and CEO of Novavax, said: "The data show that NVX-CoV2373 provides complete protection against the most serious diseases.


     

    Original source:

    Original source:

    http:// href="http://" target="_blank" rel="noopener">http:// style="vertical-align: inherit;"> http:// Leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.